

Examiner-Initiated Interview Summary	Applicati n No.	Applicant(s)	
	09/142,524	SONE ET AL.	
	Examin r	Art Unit	
	DiBrino Marianne	1644	

All Participants:

Status of Application: _____

(1) DiBrino Marianne.

(3) _____

(2) Frank C. Eisenchenk.

(4) _____

Date of Interview: 11/5/03

Time: -

Type of Interview:

☒ Telephonic

☐ Video Conference

☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☒ No

If Yes, provide a brief description:

Part I.

Rejection(s) discussed:

none

Claims discussed:

none

Prior art documents discussed:

none

Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

See Continuation Sheet

Part III.

☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.

☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

Marianne DiBrino

(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: Applicant gave permission for an Examiner's amendment: to delete "prevent and" from the abstract 2nd to last line; to amend the brief description of the drawings for figure 1 insert --(SEQ ID NO: 15-83)-- after peptides and before the period; for figure 2 insert --(SEQ ID NO: 84-156)-- after peptides and before the period; for figure 7 insert --(SEQ ID NO: 157-161)-- after "sequences" in line 1; for figure 15 insert --(SEQ ID NO: 162-173)-- after Cry j1 and before the period in line 2; for figure 17 insert --(SEQ ID NO: 174)--after "peptide" in line 2 and for figure 18 insert --(SEQ ID NO: 174) after "peptide" in line 2. .